CCL: CCG Webinar: New and Enhanced Features in MOE 2018 | Apr. 25 & May 3

 Sent to CCL by: "Dorine  Vidal" [dvidal||chemcomp.com]
 Join us for a free live webinar: New and Enhanced Features in MOE 2018.01
 Learn about the new capabilities in the latest version of the MOE
 software release, which includes applications for performing torsion
 scans and analyses, modeling natural and synthetic polynucleotide
 systems, and calculating R-group contributions to molecular properties
 through MOEsaic. We will also describe enhancements to the VCD spectral
 analysis application for predicting VCD spectra and the MOE graphical
 user interface, which now supports the HP zSpace immersive virtual
 holographic 3D visualization platform.
 Wednesday, April 25
 2:00 pm EDT | New and Enhanced Features in MOE 2018.01
 -------------------------------------------------------------------------
 - Speaker: Mike Drummond, Scientific Applications Manager, Chemical
 Computing Group
 - Moderator: Alain Deschnes, Director of Scientific Services, Chemical
 Computing Group
 - Register at: https://bit.ly/2HeJk6t
 Thursday, May 3
 10:00 a.m. EDT | New and Enhanced Features in MOE 2018.01
 -------------------------------------------------------------------------
 - Speaker: Barbara Sander, Applications Scientist, Chemical Computing
 Group
 - Moderator: Freya Klepsch, Applications Scientist, Chemical Computing
 Group
 - Register at: https://bit.ly/2HTt9st
 ==================================================
 About MOE: MOE is a leading drug discovery software platform that
 integrates visualization, modeling and simulations, as well as
 methodology development, in a single package. MOE scientific applications
 are used by medicinal chemists, biologists, crystallographers and
 computational chemists in pharmaceutical, biotechnology and academic
 research. For a more detailed software overview, please visit:
 http://www.chemcomp.com/software
 Try MOE: Request a trial version of MOE at
 http://www.chemcomp.com/Product-Trial_Request.htm
 ==================================================